I can extract side effects.

Chapter 369 Conquering HIV, Shocking the World

When Wei Kang walked into the office early in the morning, Wen Renlong rushed over to report.

"Boss, Duanailing's Phase [-] and Phase [-] clinical trial reports are out."

"Toxicology studies have found that it has no serious adverse effects on normal people and AIDS patients, and can efficiently inhibit the binding of the virus to the CCR5 receptor. The effect is as always, outstanding like me."

He raised his head, his voice was high-pitched and passionate, like a big rooster crowing.

"Through the treatment of 40 HIV adult patients, these patients took different doses of the drug alone for 10 days, and the HIV virus in the body was greatly reduced, and the reduction was the most obvious in patients who used the highest dose, reaching more than 95%."

"After the patient stopped the drug, there was no rebound in the short term, which is enough to prove the efficacy of the drug."

"The same response was seen in previously treated patients and patients who were not responding to antiretroviral therapy."

"Some mild adverse reactions were found in about 5% of patients, including diarrhea, fever, loss of appetite, etc., but these symptoms will disappear after 1-3 days of continued treatment."

"Because patients take the drug for a relatively short period of time, the long-term therapeutic effect needs to be studied in clinical phase III trials."

"In short, this drug has very high activity, low cytotoxicity, excellent pharmacodynamics, no potential drug-drug interactions, high safety, and broad prospects for the treatment of AIDS infection."

Wei Kang nodded with satisfaction: "Thank you for your hard work. In this case, the Phase III clinical trial can start immediately."

"Now many pharmaceutical companies are developing the same type of drugs, and several of them are already in the clinical stage. You should hurry up."

Wen Renlong smiled and said confidently: "Currently the only CCR5 antagonist drug that has really become the first line is Maraviro, which was launched more than ten years ago, but this drug has a lot of side effects, and there are many restrictions on its use, so It’s not really widespread.”

"Boss, don't worry, our medicine is more effective, has fewer side effects, and can eliminate HIV more thoroughly."

"We will choose maraviroc as the control group in the Phase III clinical trial, and it will definitely be contrasted sharply, killing it completely."

"Okay, then it's up to you."

In the afternoon of the same day, Sanqing Group announced the successful development of HIV specific drugs.

Not even the name "Duan Ailing" was left out.

Soon, the whole internet was shocked.

"Sanqing has successfully developed a new drug with special effects to eliminate HIV virus!"

"When HIV is no longer a terminal illness, will patients still have unspeakable secrets?"

"Humanity has finally conquered the beast of AIDS!"

"The appearance of 'Duan Ai Ling' finally made those innocent people raise their heads!"

A piece of news quickly appeared on the Internet, and related topics rushed to the top of the hot search list in just one hour.

Those small fresh meat film and television dramas that spent a lot of money on publicity have been suppressed.

When netizens saw such news, they all exploded.

"Damn it, Sanqing finally took action against HIV?"

"Great, I don't have to worry about being infected again in the future."

"Tell me your story upstairs, why are you worried about being infected? If ordinary people don't do anything wrong, the probability of being infected is extremely low."

"I still remember the hot search before. A little brother passed the public examination and came ashore. It was a happy event, but the physical examination revealed HIV. Khan, such people should not be affected in the future."

"This kind of person deserves to be found out for his indiscretion. Those who are infected because of blood donation are pitiful. I have read reports from the AIDS village. It is so pitiful. Most of the villagers are old, weak, sick and disabled, and they are all infected. Yes, it's a crime."

"With the medicine of Sanqing, there should be no more incidents in the AIDS village."

"The most pitiful thing is a baby who was born with AIDS. He didn't do anything. When he came into this world, he was hit head-on. It's too cruel."

"These people are very pitiful. The incident of editing the baby that was sentenced before was the effort that the parents carried the HIV virus to give birth to a healthy baby. If they had this drug, they would not have done that. .”

"Except for those messing around, the other infected people are innocent and pitiful. They desperately need such special medicine to save their lives."

"What qualifications are there for those who are sick to take this medicine? They asked for it themselves. Now that they can be cured, they will definitely be more messy in the future. It is really hard to prevent."

"The hospital has to protect the privacy of this kind of person. They can't tell their relatives. A friend of mine's husband was infected. I kept it from her during the premarital examination, but he was infected after marriage. What a tragedy."

"In the future, AIDS will be an ordinary infectious disease, just like hepatitis A and hepatitis B. In this way, patients should not need to hide it everywhere. It seems to be a good thing."

"I hope so. Be careful, everyone. Maybe someone close to you will be exposed soon, saying that you are an HIV carrier. You kept it a secret before. Now that you can cure it, let's see how they keep it a secret."

"I hope, anyway, when I see this kind of person in the future, I will hide away."

From the reactions of netizens, it can be seen that after more than ten years of unremitting publicity by the media, AIDS has already made people frightened.

The main reason is the high concealment and high infectivity of the HIV virus. The incubation period of HIV in the human body is as high as 8 years. During this period, HIV can live without any symptoms for many years.

Some people like to look for excitement after they live a worry-free life, and they are more open to certain things, so they are easy to get caught accidentally.

Some people were infected by some carriers who retaliated against the society. After these people contracted the disease themselves, due to the pessimism brought about by terminal illness, they tended to develop a revenge mentality. Why should others be fine when they are fine?

Someone passed it on to him, and he also passed it on to others. If there is bad luck, everyone will have bad luck together.

With such thoughts, it spreads everywhere, which is really hard to guard against.

This also leads to people's fear of this disease, which is higher than other terminal diseases.

After all, common terminal illnesses are not contagious, so they don't have to worry.

This is why AIDS has become a public health problem, and one million infected people across the country can receive free drug treatment at the CDC.

While netizens were discussing enthusiastically, the news quickly spread overseas.

All along, Sanqing's every move has been watched by many competitors.

Generally speaking, when pharmaceutical companies deploy hot tracks and invest in new drugs, they must keep abreast of the latest news in the industry in order to more intuitively view the competitive landscape of a certain product.

Especially in the fiercely competitive pipeline track, various pharmaceutical companies are making efforts to launch their own new drugs for the same target.

This means that if the same type of drug crashes, if the opponent develops it before you and passes the clinical market before you, it may completely occupy all the opportunities.

Especially for some breakthrough first-in-class drugs, the first to be developed can often go through the green channel and quickly pass the review and go on the market, while the latecomers do not have such treatment.

Often the first drug can be launched quickly in a few months, but the second drug has to go through the conventional channel, and it will take two or three years to get to the market.

Not only will it be one step behind and lose the opportunity to seize the market, but sometimes seeing that the other party has too much advantage, the pharmaceutical company will even directly abandon the project and terminate the clinical trial. In this way, all the R&D investment in the early stage will be completely wasted.

The track of anti-AIDS drugs is undoubtedly the kind with extremely fierce competition.

The target of CCR5 antagonists is also quite popular.

Therefore, the first ones that can't sit still are the companies that develop CCR5 antagonists.

Especially those pharmaceutical companies that have achieved results and entered the clinical stage.

Eagle Country, Merck headquarters.

A board meeting is being held urgently.

All the directors felt very helpless when they saw the news in front of them.

After 15 years, Sanqing has developed a CCR5 antagonist?

It's nothing, but it's a collision with a new anti-HIV drug of the company.

As a small-molecule antagonist targeting the CCR5 target, Merck's new drug has entered phase 2 clinical trials.

The data in all aspects are excellent, and after a series of structural modifications, the adverse reactions are also greatly reduced.

The company has always been optimistic about it, and wants to rely on this drug to make a beautiful turnaround in the field of anti-AIDS drugs.

In the global AIDS drug market, Gilead, GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMS), Merck, and Johnson & Johnson are the most important companies. Although Gilead is the absolute overlord, it is following No. .2GSK played hard.

But Merck can get a share of the more than 300 billion US dollars anti-AIDS drug market, and it also has several drugs with good curative effects.

It's just that the presence in the global market is very low.

CRR5 is indeed a popular target. There are many new drugs under development, but none of them can enter the third phase of clinical trials.

It is very rare for their drug to enter the clinical phase 2.

However, this Sanqing is simply a freak.

Suddenly, a new anti-AIDS drug was developed, and it entered the third phase of clinical trials.

They just don't talk about Wude, and in this way, their new medicine will collide with Sanqing's new medicine.

Looking at the clinical phase II data disclosed by Sanqing, all the directors fell silent.

Blind people can see the efficacy of this new drug, and it will definitely beat their new drug with the same target.

Also, if they can develop a new drug comparable to Sanqing, they will not be defeated by Gilead.

Merck's chief pharmaceutical expert sighed: "I'm sorry, the data of this drug is perfect, it seems that we lost this time."

"I propose to give up this CCR5 antagonist. We have several new anti-AIDS drugs targeting different targets. We can put resources on other projects, which may be more promising." A director said .

"However, in this way, Gilead is at the top, and Sanqing is constantly chasing after us. It is very uncomfortable for us to be caught in the middle, especially since we are still relatively backward, and we are likely to watch Sanqing take our market. Grab them all."

"The anti-AIDS drug market, sooner or later we will lose it completely."

"For this special drug, the FDA of various countries will definitely simplify the approval process and let it go on the market as soon as possible. There is not much time left for us."

"He is already in the third phase of clinical trials, and we are only in the second phase, so why don't we catch up?"

"Maybe the company should consider changing the direction of research and development."

The directors began to discuss in one go.

In the end, they still made the decision to abandon this clinical phase 2 drug.

Also paying attention to the three new drugs are GSK, Gilead, BMS, Johnson & Johnson and other companies.

These top pharmaceutical companies all have a lot of territory in the anti-AIDS drug market, and they are all shocked by this.

Seeing that in this crowded market, a new player will be added to disturb the market structure.

They instantly felt a deep crisis.

As one of the overlords of anti-AIDS drugs who sit and watch the clouds rise and fall, I am not moving. GSK said that this little brother is a bit fierce.

The knife came hard from behind, it may not be able to catch it.

After decades of continuous evolution of HIV drug therapy, from the single-drug 1.0 era, to the 2.0 era of cocktail therapy, and then to the 3.0 era of complete cure in the future, it fully demonstrates the vigorous development of human science and technology.

From the earliest discovery of HIV to the FDA's approval of the first treatment drug, people didn't have to wait long.

In the 80s, GSK developed the first human weapon against HIV, and it went on the market through rapid review, bringing hope of survival to HIV-infected people for the first time.

At this point, HIV drug treatment officially opened the 1.0 era.

However, the first generation of antiretroviral drugs is obviously still relatively backward and cannot keep up with the changing process of HIV, so patients would still get sick and die quickly at that time.

After the 90s, various new anti-HIV mechanisms gradually emerged, and a series of new HIV drugs such as protease inhibitors and fusion inhibitors began to increase rapidly.

HIV treatment has suddenly been freed from the difficult dilemma of monotherapy options.

In this context, the team of Chinese American scientist Professor He proposed a brand-new combined drug delivery strategy - Highly Active Antiretroviral Therapy (HAART), which was later commonly known as cocktail therapy.

Because it can both stop the HIV virus from multiplying and prevent drug-resistant viruses in the body, the cocktail therapy quickly became the standard treatment for HIV.

This was a revolutionary breakthrough. GSK seized the opportunity and followed up quickly. It was the first to launch the triple compound therapy, which reduced the mortality rate by more than half, and became the leader in HIV treatment drugs.

In addition to GSK, Gilead, Merck, Johnson & Johnson and other pharmaceutical giants also quickly joined the layout of HIV cocktail therapy.

So far, HIV drug administration has changed from multiple times a day to once a day, and then to once every half a month, which has greatly improved treatment compliance.

More importantly, HIV treatment has also completed a perfect transformation from the confused period of the 1.0 era and entered the 2.0 era.

HIV is gradually becoming a manageable chronic disease.

Data show that during this period, the number of global HIV deaths has also dropped from 190 million to nearly 100 million. In other words, the ever-evolving HIV drugs have saved millions of lives.

In this process, GSK is the pioneer of HIV therapy. It has the first HIV treatment drug and the first cocktail therapy, and has established an absolute dominance in the early HIV drug market. In the HIV competition where almost only multinational pharmaceutical giants enter Dao, firmly pressing the old opponents under him one by one.

However, GSK did not sit firmly on the top spot for a long time. In 06, after Gilead launched Atripla, with its good clinical efficacy and low cost, it beat GSK steadily in just a few years. retreat.

Since then, Gilead has officially replaced GSK as the global leader in the HIV market.

With the birth of Biktarvy in 18, it swept the world in the second year after its launch and reached sales of 73 billion US dollars, becoming the king of HIV drugs.

Bitovex helped Gilead once occupy more than 60% of the global HIV drug market share, and it still maintains a high growth rate of 8%. For now, no drug can shake its position.

In contrast, GSK's situation in recent years has been a bit sad. Although it still has several blockbuster drugs, its growth is hardly optimistic, and its sales fell by 30% last year.

As a veteran giant, GSK will not choose to sit still, but will soon develop a new long-acting injection drug that can be injected once a month.

The script seems to be so familiar again. GSK has mastered the revolutionary technology and took the lead in making efforts, but this time GSK has become the challenger, and Gilead has become the responder.

It can be said that both sides have played out their brains.

At this moment, although Sanqing's new HIV drug arrived late, the future can be expected.

In one fell swoop, anti-AIDS drugs will be pulled into the era of 3.0 that can be cured.

Although it is still necessary to take medicine for a long time like a chronic disease, it can indeed be cured and the virus in the body can be completely removed.

The era of HIV treatment 1.0 and 2.0 has become history, and the era of HIV treatment 3.0 has begun.

After decades of fighting, HIV has finally become a controllable chronic disease from a super cancer at the beginning.

This is the progress of science and the luck of mankind.

(End of this chapter)